MetaCap

Amarin (AMRN) vs CytomX Therapeutics (CTMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amarin (AMRN) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 35.5% versus a loss of 47.7%. Over five years, CTMX leads with a -69.9% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $442.5 million), about 1.0 times the size.

Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -22.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%CTMX-47.68%
+80%+11%-58%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%CTMX-72.34%
+5%-47%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus CTMX key metrics
MetricAMRNCTMX
Share price$10.57$2.03
Market cap$444.39M$442.55M
1-day change-6.13%-0.98%
YTD return-24.28%-52.35%
1-year return-35.47%-47.68%
5-year return-85.48%-69.93%
Forward P/E10.79—
EPS (TTM)$-0.80$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$76.20M
Revenue growth (YoY)-6.55%-44.82%
Net income (latest FY)$-38.80M$-17.37M
Gross margin56.57%—
Operating margin-23.48%-29.35%
Net margin-18.16%-22.79%
52-week high$17.31$8.21
52-week low$10.56$1.87
Distance from 52-week high-38.94%-75.27%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+509.85%
Average volume79.50K4.27M
Shares outstanding42.04M218.00M
Employees8069
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMRN has outperformed CTMX by 12.2 percentage points over the past year.
  • Amarin grew revenue faster in its latest fiscal year (-6.55% vs -44.82%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

AMRN vs CTMX FAQ

Which is bigger, Amarin or CytomX Therapeutics?

Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $442.55M for CytomX Therapeutics (CTMX).

Which stock has performed better over the past year, AMRN or CTMX?

AMRN returned -35.47% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and CytomX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons